PURPOSE OF REVIEW: An improved understanding of the psoriasis pathogenesis has provided new insights into potential new therapeutic targets, which has positively influenced the development of novel therapies. This monograph reviews recent clinical trials concerning new small molecules and biotech products under investigation for plaque psoriasis treatment. Emphasis is placed on mechanism of action, efficacy and adverse effects of these new agents. RECENT FINDINGS: Recent literature has shown that there are several new drugs under development for psoriasis treatment including new A3 adenosine receptor agonists, biologics like anti-tumor necrosis factor, anti-interleukin-17, anti-interleukin-12/23 and anti-interleukin-17 receptor agents, as well as Janus kinase and phosphodiesterase 4 inhibitors, among others. Although clinical trials were too short for predicting the real long-term safety of these treatments, other studies longer than those presently available are expected in the future. SUMMARY: On the basis of novel advances in psoriasis therapy, treatment paradigms could change in the following years. However, the real contribution of these new drugs to the antipsoriatic therapeutic armamentarium still needs to be established.
PURPOSE OF REVIEW: An improved understanding of the psoriasis pathogenesis has provided new insights into potential new therapeutic targets, which has positively influenced the development of novel therapies. This monograph reviews recent clinical trials concerning new small molecules and biotech products under investigation for plaque psoriasis treatment. Emphasis is placed on mechanism of action, efficacy and adverse effects of these new agents. RECENT FINDINGS: Recent literature has shown that there are several new drugs under development for psoriasis treatment including new A3 adenosine receptor agonists, biologics like anti-tumornecrosis factor, anti-interleukin-17, anti-interleukin-12/23 and anti-interleukin-17 receptor agents, as well as Janus kinase and phosphodiesterase 4 inhibitors, among others. Although clinical trials were too short for predicting the real long-term safety of these treatments, other studies longer than those presently available are expected in the future. SUMMARY: On the basis of novel advances in psoriasis therapy, treatment paradigms could change in the following years. However, the real contribution of these new drugs to the antipsoriatic therapeutic armamentarium still needs to be established.
Authors: Manju Sharma; Corey Levenson; Ian Clements; Paul Castella; Kurt Gebauer; Michael E Cox Journal: Front Pharmacol Date: 2017-03-16 Impact factor: 5.810